Targeting MALT1 in B-cell Lymphomas

Summary:

Safimaltib, a selective allosteric MALT1 protease inhibitor, shows potent antitumor activity in preclinical and clinical studies of B-cell non-Hodgkin lymphomas.

See related article by Philippar et al., p. XX

See related article by Hertzberg et al., p. XX